Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
06/2000
06/22/2000WO2000035443A1 Method and composition for the maintenance and restitution of gut integrity
06/22/2000WO2000035436A2 Treatment of arthritis with mek inhibitors
06/22/2000WO2000035435A1 Use of a mek inhibitor for preventing transplant rejection
06/22/2000WO2000035434A2 Compositions and methods for the treatment of anorectal disorders
06/22/2000WO2000035428A2 Tricyclic nitrogen heterocycles as pde iv inhibitors
06/22/2000WO2000035425A1 STABLE PHARMACEUTICAL FORMULATION COMPRISING A HMG-CoA REDUCTASE INHIBITOR
06/22/2000WO2000035423A1 Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same
06/22/2000WO2000035407A2 Inhibition of angiogenesis by high molecular weight kininogen domain 3 peptide analogs
06/22/2000WO2000016632A3 Environmentally benign crop protection agents
06/22/2000WO2000015244A3 Pharmaceutical preparation containing a cyclopeptide and a chemotherapeutic agent or an angiogenesis inhibitor
06/22/2000WO2000014106A9 Novel bag proteins and nucleic acid molecules encoding them
06/22/2000WO2000011033A3 Expression and export of angiostatin and endostatin as immunofusins
06/22/2000WO2000007624A3 Pharmaceutical composition having inhibitory effect on overproduction and accumulation of extracellular matrix
06/22/2000WO2000004954A3 Novel urokinase inhibitors
06/22/2000WO2000002542A3 Agents with an antidepressive effect containing pramipexol and an additional antidepressant drug
06/22/2000WO2000000158A9 Alkylamines and their precursors as specific modulators of human gamma-delta t cell function
06/22/2000WO1999059615A9 Hybrid polypeptides with enhanced pharmacokinetic properties
06/22/2000WO1999048488A3 Methods for decreasing beta amyloid protein
06/22/2000CA2362423A1 47 human secreted proteins
06/22/2000CA2355936A1 A flowable drug precursor product and a process for preparing same
06/22/2000CA2355714A1 7-aryl-6(z)heptatrienoic acid retinamides as apoptosis inducing compounds and their use as anti-cancer agents
06/22/2000CA2355650A1 Methods and compositions for decreasing allergic reactions to surface allergens
06/22/2000CA2355363A1 Prostacyclin-stimulating factor-2
06/22/2000CA2355287A1 Inhibition of angiogenesis by high molecular weight kininogen domain 3 peptide analogs
06/22/2000CA2355249A1 Protease inhibitors
06/22/2000CA2355234A1 Quinoline derivatives
06/22/2000CA2355211A1 Aldose reductase inhibitors and pharmaceutical compositions
06/22/2000CA2355202A1 Imidazolones and their use in treating benign prostatic hyperplasia and other disorders
06/22/2000CA2355201A1 Morpholinone and morpholine derivatives and uses thereof
06/22/2000CA2355066A1 Extending graft survival by heme oxygenase-i expression induced immunomodulation
06/22/2000CA2354875A1 Piperazine derivatives
06/22/2000CA2354873A1 4-alkenyl (and alkynyl) oxindoles as inhibitors of cyclin-dependent kinases, in particular cdk2
06/22/2000CA2354591A1 4-aryloxindoles as inhibitors of jnk protein kinases
06/22/2000CA2354543A1 Compositions and methods for the treatment of anorectal disorders
06/22/2000CA2354456A1 Connective tissue growth factor fragments and methods and uses thereof
06/22/2000CA2354422A1 Connective tissue growth factor fragments and methods and uses thereof
06/22/2000CA2354402A1 4,5-pyrazinoxindoles as protein kinase inhibitors
06/22/2000CA2354061A1 Arylpiperidine and aryl-1,2,5,6-tetrahydropyridine amide derivatives having 5ht1a receptor activity
06/22/2000CA2353997A1 Therapeutic and diagnostic uses of protein tyrosine phosphatase tc-ptp
06/22/2000CA2353924A1 Cyclic hydrazine derivatives as tnf-alpha inhibitors
06/22/2000CA2353561A1 Human brain endothelial cells and growth medium and method for expansion of primitive cd34+cd38- bone marrow stem cells
06/22/2000CA2353151A1 Substituted aryl and heteroaryl derivatives, the preparation thereof and their use as medicaments
06/22/2000CA2352631A1 Optical molecular sensors for cytochrome p450 activity
06/22/2000CA2352570A1 Methods and compositions for treating disorders involving excitotoxicity
06/22/2000CA2351860A1 Piperazine ethylamide derivatives with 5-ht1a receptor activity
06/22/2000CA2351859A1 1,4-piperazine derivatives having 5ht1a receptor activity
06/22/2000CA2351469A1 Method and composition for the maintenance and restitution of gut integrity
06/22/2000CA2351464A1 3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesion mediated by vla-4
06/22/2000CA2351400A1 Arylpiperidine and aryl-1,2,5,6-tetrahydropyridine urea derivatives having 5ht1a receptor activity
06/22/2000CA2346684A1 Use of a mek inhibitor for preventing transplant rejection
06/22/2000CA2346448A1 Treatment of arthritis with mek inhibitors
06/22/2000CA2345752A1 Tricyclic nitrogen heterocycles as pde iv inhibitors
06/21/2000EP1010698A1 1,2-dithiolane derivatives, their process of preparation and pharmaceutical compositions containing them
06/21/2000EP1010694A2 Spiroimidazoline derivatives and their use as alpha2-adrenergic antagonists and monoamines-reuptake blockers
06/21/2000EP1010693A1 Imidazoline derivatives, preparation and pharmaceutical compositions containing them
06/21/2000EP1010691A2 Hydrazide derivatives, process for their preparation and pharmaceutical compositions containing them
06/21/2000EP1010431A2 Botulinum toxins for treating pain associated with muscle spasms
06/21/2000EP1009829A1 Adipocyte-specific protein homologs
06/21/2000EP1009826A1 Erbb4 receptor-specific neuregulin, related ligands and uses thereof
06/21/2000EP1009755A1 Steroid sulfatase inhibitors and methods for making and using the same
06/21/2000EP1009743A1 Certain benzothiazine dioxide endothelin antagonists and processes for their preparation
06/21/2000EP1009741A1 Novel carboxylic acid derivatives, their production and their use as mixed et a?/et b? endothelin-receptor antagonists
06/21/2000EP1009739A2 Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
06/21/2000EP1009738A1 Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors
06/21/2000EP1009737A2 Sulfonylamino substituted hydroxamic acid derivatives as metalloprotease inhibitors
06/21/2000EP1009736A1 Malonic acid based matrix metalloproteinase inhibitors
06/21/2000EP1009732A2 1-amino-alkylcyclohexane nmda receptor antagonists
06/21/2000EP1009442A1 Improvements in or relating to regulation of t cell activation
06/21/2000EP1009433A1 Therapeutic composition and method of treatment
06/21/2000EP1009432A1 Composition and method to prevent graft rejection and other counter-adaptive t lymphocyte mediated immune responses
06/21/2000EP1009431A1 Human tumor necrosis factor receptor-like 2 (tr2) antibodies
06/21/2000EP1009426A1 Method for treating a subject suffering from conditions associated with an extracellular zinc sphingomyelinase
06/21/2000EP1009425A1 Wound healing
06/21/2000EP1009422A1 STRUCTURE OF THE ANKYRIN BINDING DOMAIN OF A ALPHA-Na,K-ATPase
06/21/2000EP1009415A1 INHIBITORS OF $g(b)-LACTAMASES AND USES THEREFOR
06/21/2000EP1009412A1 Use of purine nucleosides for modulating the axonal outgrowth of central nervous system neurons
06/21/2000EP1009411A1 Method and composition for treating sleep apnea
06/21/2000EP1009402A4 Compositions and use of benzamides and nicotinamides as anti-inflammatory agents
06/21/2000EP1009402A1 Compositions and use of benzamides and nicotinamides as anti-inflammatory agents
06/21/2000EP1009377A1 Medical uses of pyruvates
06/21/2000EP1009345A1 Skin aging and wound treatment using cell migration agents
06/21/2000EP1009232A1 Methods for treating insulin resistance and identifying patients at risk for the disease
06/21/2000EP0825875B1 Therapeutic composition comprising an antigen or an in vivo generator for generating a compound comprising an amino acid sequence
06/21/2000DE19916224C1 Synthetic molecule for delivering active ingredient to cell, used e.g. to treat human immune deficiency virus infection, comprises the ingredient linked to VP2 or 3 peptide from polyoma virus
06/21/2000DE19858779A1 New 3-acylamino-propionic acid and 3-sulfonylamino-propionic acid derivatives useful as endothelin receptor antagonists in treatment of e.g. cardiovascular and renal disorders, migraine and cancer
06/21/2000DE19858463A1 Verwendung eines Fibrinklebers zur Regeneration des Lebergewebes Use of fibrin glue for the regeneration of liver tissue
06/21/2000DE19858331A1 Tricyclische Stickstoffheterocyclen als PDE IV Inhibitoren Tricyclic nitrogen heterocycles as PDE IV inhibitors
06/21/2000DE19857816A1 Fließfähige, pressfertige Arzneimittelvorprodukte für Tabletten, Pellets und Dragees, sowie Verfahren zu deren Herstellung Flowable, press-ready drug precursors for tablets, pellets, and dragees, and to processes for their preparation
06/21/2000CN1257545A Type II TGF-beta receptor/immunoglobulin constant region fusion proteins
06/21/2000CN1257538A Short peptides which selectively modulate the activity of serine/threonine kinases
06/21/2000CN1257510A New BPC peptide salts with organo-protective activity, the process for their preparation and their use in therapy
06/21/2000CN1257504A Salts of aromatic sulphonic acids
06/21/2000CN1257503A 2-amino-7-(1-substituted-2-hydroxyethyl)-3,5-dihydro-pyrrolo (3,2-D] pyrimidine-4-ones
06/21/2000CN1257500A 9-azabicyclo (3,3,1) non-2-ene and nonane derivatives as cholinergic ligands at nicotinic ACH receptors
06/21/2000CN1257499A 8-Azabicyclo (3,2,1) oct-2-ene and octane derivatives as cholinergic ligands at nicotinic ACH receptors
06/21/2000CN1257497A Sulfate salt of an HTV protease inhibitor having an improved oral absorption and bioavailability
06/21/2000CN1257489A Substituted benzopyran derivatives for the treatment of inflammation
06/21/2000CN1257485A Azacyclooctane and heptane derivatives, their preparation and usein therapy
06/21/2000CN1257482A Quinoline-2-carboxylic acid derivative and its use as excitatory amino acids antagonist
06/21/2000CN1257481A Novel pyridine derivatives and pharmaceutical compositions containing them
1 ... 1150 1151 1152 1153 1154 1155 1156 1157 1158 1159 1160 1161 1162 1163 1164 1165 1166 1167 1168 1169 1170 ... 1564